Effect of Factor XIII on Endothelial Barrier Function
Open Access
- 3 May 1999
- journal article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 189 (9) , 1373-1382
Abstract
The effect of factor XIII on endothelial barrier function was studied in a model of cultured monolayers of porcine aortic endothelial cells and saline-perfused rat hearts. The thrombin-activated plasma factor XIII (1 U/ml) reduced albumin permeability of endothelial monolayers within 20 min by 30 ± 7% (basal value of 5.9 ± 0.4 × 10−6 cm/s), whereas the nonactivated plasma factor XIII had no effect. Reduction of permeability to the same extent, i.e., by 34 ± 9% could be obtained with the thrombin-activated A subunit of factor XIII (1 U/ml), whereas the iodoacetamide-inactivated A subunit as well as the B subunit had no effect on permeability. Endothelial monolayers exposed to the activated factor XIII A exhibited immunoreactive deposition of itself at interfaces of adjacent cells; however, these were not found on exposure to nonactivated factor XIII A or factor XIII B. Hyperpermeability induced by metabolic inhibition (1 mM potassium cyanide plus 1 mM 2-deoxy-d-glucose) was prevented in the presence of the activated factor XIII A. Likewise, the increase in myocardial water content in ischemic-reperfused rat hearts was prevented in its presence. This study shows that activated factor XIII reduces endothelial permeability. It can prevent the loss of endothelial barrier function under conditions of energy depletion. Its effect seems related to a modification of the paracellular passageways in endothelial monolayers.Keywords
This publication has 34 references indexed in Scilit:
- Therapeutic Factor XIII Preparations and Perspectives for Recombinant Factor XIIISeminars in Thrombosis and Hemostasis, 1996
- Factor XIII in Chronic Inflammatory Bowel DiseasesSeminars in Thrombosis and Hemostasis, 1996
- Factor XIII Deficiency: Pathogenic Mechanisms and Clinical SignificanceSeminars in Thrombosis and Hemostasis, 1996
- Factor XIII: Inherited and acquired deficiencyBlood Reviews, 1993
- Successful treatment of adult Henoch-Schönlein purpura with factor XIII concentrateJournal of the American Academy of Dermatology, 1991
- Vitronectin is a substrate for transglutaminasesBiochemical and Biophysical Research Communications, 1988
- b-chains prevent the proteolytic inactivation of the a-chains of plasma factor XIIIBiochimica et Biophysica Acta (BBA) - General Subjects, 1988
- Role of fibronectin in the migration of fibroblasts into plasma clots.Journal of Cell Biology, 1986
- Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa.Journal of Clinical Investigation, 1979
- Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIIICell, 1976